An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A telehealth company called Ozari Health is now offering compounded versions of two popular weight-loss and diabetes drugs—semaglutide and tirzepatide—throughout the United States, with prices starting around $86 per month for semaglutide and $125 per month for tirzepatide. This was reported as part of an updated 2026 data snapshot on GLP-1 pricing. The announcement is basically: you can get cheaper, compounded forms of these medicines online through Ozari’s platform. Semaglutide and tirzepatide are drugs that act like hormones your body uses to control blood sugar and appetite. Semaglutide is the active ingredient in brand-name drugs like Ozempic and Wegovy; it mimics a gut hormone that helps you feel full and slows how fast your stomach empties. Tirzepatide is a newer drug that combines effects on two different gut hormones, so it tends to lower appetite and blood sugar even more in some studies. “Compounded” means a pharmacy mixes the drug specifically for a prescription, rather than it coming in a factory-sealed vial from the brand-name manufacturer. What the announcement itself shows is mostly about price and availability, not new medical research. It says Ozari will provide compounded versions nationwide and lists starting prices. There’s no new study data in the report; it doesn’t show whether Ozari’s compounded products work better, worse, or exactly the same as brand-name versions. The source also ties this offer to updated 2026 pricing data for GLP-1 drugs overall, which is useful for comparing costs but not for judging safety or effectiveness. Why this matters is straightforward: many people want access to these medicines because of their effects on weight and blood sugar, and cost and availability have been major barriers. If compounded options are cheaper and legally prescribed after a telehealth visit, more people might be able to start treatment. That could be especially important for people without good insurance coverage for brand-name GLP-1 drugs or those in areas without nearby clinics. There are important cautions. Compounded drugs are not the same as FDA-approved brand products; they aren’t evaluated in the same way for consistency, purity, or effectiveness. Quality can vary between compounding pharmacies. Also, telehealth prescribing should include medical screening and monitoring, because these drugs can cause side effects like nausea, vomiting, low blood sugar in people on other diabetes meds, and rarely more serious issues. People with certain conditions or who are pregnant shouldn’t take these medicines without careful medical advice. The report doesn’t say which compounding pharmacies Ozari uses or what safety checks are in place, so ask for details before starting treatment. Bottom line: Ozari is offering lower-cost compounded semaglutide and tirzepatide via telehealth, which may improve access, but compounded versions differ from brand-name products and you should confirm quality, proper medical oversight, and safety before deciding to use them.
Source: The Manila Times